2019 LakePharma Symposium

LakePharma Symposium - 2019


LakePharma 2019 Symposium successfully covered topics in cell and gene therapies. The conference was well received by over 300 attendees and vendors. 

Date:

Thursday, October 10, 2019

Location:

South San Francisco Conference Center, 255 South Airport Boulevard, South San Francisco, CA 94080

Organizing Committee:

Hua Tu, Ph.D.                                  CEO, LakePharma, Inc.

Norman Garceau, Ph.D.                  VP, Technical Operations, LakePharma, Inc.

Brian Zabel, Ph.D.                           Senior Director, Discovery Immunology, LakePharma, Inc.

Speakers:

 

 

Alan Ashworth, Ph.D., FRS
President of Helen Diller Family Comprehensive Cancer Center at UCSF

Michael Boychyn, Ph.D.
Vice President of Process
Development at REGENXBIO Inc.

Dean Felsher, MD, Ph.D.
Director of Oncology Research, 
Director of Translational Research
and Applied Medicine at Stanford
University

Everett Meyer, MD, Ph.D.
Medical and Scientific Director,
Cellular Therapy Facility
at Stanford University

Madhusudan Peshwa, Ph.D.
Chief Technology Officer of Global Cell
Therapy at GE Healthcare

David Schaffer, Ph.D.
Director of the Berkeley
Stem Cell Center at UC Berkeley

Hua Tu, Ph.D.
President and CEO of LakePharma

  

       Pam Contag Ph.D.
          CEO, Bioeclipse
 
 

Schedule:

8:00 am -  5:30 pm, Thursday October 10, 2019      View full agenda here >>  |  Download PDF here >>

 

Agenda:

Directed Evolution of Novel Adeno-Associated Viral Vectors for Clinical Gene Therapy, David Schaffer, Ph.D., UC Berkeley

 

A Platform for Identifying Strategies for Reversing Cancer and Restoring the Immune Response, Dean Felsher, MD, Ph.D., Stanford University

 

Synthetic Lethal Approaches to Cancer Therapy, Alan Ashworth, Ph.D. FRS, UCSF

 

Clinical and Pre-Clinical Approaches Using T Regulatory Cells to Prevent or Treat Graft-versus-Host Disease, Everett Meyer, MD, Ph.D., Stanford University

 

The Combination of Immune Cells and Oncolytic Virus Creates A Unique Multi-Mechanistic Biotherapy for Treatment of Refractory Solid Tumors, Pam Contag, Ph.D., Bioeclipse

 

Comparison of Baculovirus (BV)-Sf9 and HEK293 Expression Systems for the Production of Adeno-Associated Virus (AAV) Vectors, Michael Boychyn, Ph.D., REGENXBIO

 

Industrializing the Manufacture of Cell and Gene Therapies, Madhusudan Peshwa, Ph.D., GE Healthcare

 

From CRO to CRDMO, LakePharma's Technology Development in Meeting Next-Generation Therapeutics Needs, Hua Tu, Ph.D., LakePharma

 

 

Parallel Lunch Workshops:

Alt-R CRISPR Genome Editing: Innovation Driving Solutions for HDR, Specificity, and Off-Target Analysis
Integrated DNA Technologies, Inc. | View Abstract

 

Integrated Workflow Solutions for Development of Cellular Therapies
Thermo Fisher Scientific | View Abstract

 

Expanding SPR Throughput Orders of Magnitude to Accelerate Therapeutic Antibody Discovery
Carterra | View Abstract

 

Panel Discussion on Cell Therapy GMP Manufacturing
LakePharma  | View Abstract

Announcements:

Please contact symposium@lakepharma.com for more information.



  • Sponsors:

‚Äč